金融界8月8日消息，周五，港股集体低开，恒生指数跌0.45%报24968.31点，恒生科技指数跌0.83%报 5500.85点，国企指数跌0.55%报8932.42点，红筹指数跌0.06%报4262.42点。 盘面上，大型科技股中多数下跌，阿里巴巴跌0.5%，小米集团跌0.87%，网易跌1.45%，美团跌0.82%， 快手跌0.69%，哔哩哔哩跌1.36%；港股黄金股高开，赤峰黄金涨4.9%，潼关黄金涨3.6%，山东黄金、 灵宝黄金纷纷高开；中芯国际净利润同比下降19%绩后跌超4%。中资券商股普遍高开，申万宏源涨近 1%；脑机接口概念活跃，脑洞科技涨超8%。 企业新闻 中国移动(00941.HK)：上半年收入5438亿元，通信服务收入为4670亿元，同比增长0.7%；净利润842亿 元，同比增5%。 中芯国际(00981.HK)：上半年销售收入为44.6亿美元，同比增长22%；二季度销售收入22.09亿美元，环 比下降1.7%。 华虹半导体(01347.HK)：二季度销售收入5.66亿美元，同比增加18.3%；净利润800万美元，同比增加 19.2%。 美高梅中国(02282.HK)：上半年收入约166.61 ...

Group 1 - The article announces the exclusive launch of the only "Pharmaceutical ETF" in the market, which includes leading companies in chemical drugs, biological drugs, and traditional Chinese medicine, starting from August 8 [1][3] - The pharmaceutical industry is characterized by its strong demand attributes, driven by a large population base, accelerated aging, and rising GDP per capita, indicating a long-term high prosperity in the sector [3][4] - By 2024, the proportion of the population aged 65 and above in China is expected to reach 15.6%, marking the entry into a moderately aging society, which will further expand the pharmaceutical market space [4] Group 2 - The innovative drugs are seen as a typical representative of new productive forces, expected to drive the revaluation of medical assets and open up growth ceilings for the pharmaceutical industry [4] - The domestic innovative drug market is predicted to experience significant growth, with the potential for a "Davis Double Hit" in 2024 due to multiple internal and external catalysts [4] - The pharmaceutical index has shown a significantly smaller decline compared to similar indices over the past five years, with positive returns in the last three years [14][15] Group 3 - The pharmaceutical index includes leading listed companies in the three major pharmaceutical sectors: chemical drugs, biological drugs, and traditional Chinese medicine, reflecting the overall performance of pharmaceutical theme stocks [7][11] - The top ten constituent stocks of the pharmaceutical index include major companies such as Heng Rui Pharmaceutical, with a market capitalization of 374.3 billion yuan, and Yunnan Baiyao, with a market capitalization of 100.9 billion yuan [12][13] - The current point of the pharmaceutical index is still at the level before the last major market rally, indicating a high cost-performance ratio for investment [16]

Market Overview - The A-share market has shown signs of recovery, leading to a strong rebound in actively managed equity funds, with over 90% of products seeing net value increases this year, and 1,126 funds reaching new highs since their inception [1][2] - As of August 7, the Shanghai Composite Index rose by 0.16% to 3,639.67 points, marking a new annual high, while the Shenzhen Component Index and the ChiNext Index experienced slight declines [1] Fund Performance - The year has seen significant performance divergence among actively managed equity funds, with top performers achieving returns close to 130%, while the worst performers faced declines exceeding 18% [2] - The leading sectors contributing to fund performance include innovative pharmaceuticals, hard technology, and new consumption, prompting many high-performing funds to limit purchases and new products to attract capital [2] Fund Issuance and Dividends - On August 7, 10 new funds were launched, primarily focusing on bond and equity types, with a notable fundraising target of 6 billion yuan for the CITIC Prudential Stable and Interest Rate Bond Fund [2] - A total of 15 funds declared dividends, with the highest payout being 3.8419 yuan per 10 shares from the Guotai Junan Jinan Energy Heating Closed Infrastructure Securities Investment Fund [2] Fund Registration Trends - The recovery in the A-share market has led to a surge in private securities product registrations, with 1,298 products registered in July alone, a month-on-month increase of 18%, marking a 27-month record [2] - Year-to-date, a total of 6,759 products have been registered, reflecting a year-on-year increase of 61.39%, with index-enhanced strategies seeing a 52% increase in registrations [2] Top Performing Funds - The best-performing fund on August 7 was the Qianhai Kaiyuan Hong Kong-Shenzhen Core Resource Mixed Fund C, with a daily growth rate of 5.2471%, followed closely by its counterpart A [4] - In the stock fund category, the top performer was the Huabao CSI Rare Metals Index Enhanced Fund A, with a daily growth rate of 2.3076% [5]

Group 1: Macro Insights - In July, China's exports exceeded expectations, primarily driven by the EU, ASEAN, and other emerging markets. However, the introduction of a 40% transit tariff by the US may impact re-export trade, increasing the likelihood of a decline in exports [2] - Despite potential export declines, the recovery of European manufacturing and ongoing expansion in emerging markets are expected to provide support for exports to the EU, Africa, and the Middle East [2] Group 2: Convertible Bond Strategy - The report indicates that as equity indices continue to rise and demand for fixed income remains strong, the valuation of convertible bonds is approaching high levels, leading to some profit-taking by absolute return funds. However, if the equity market does not experience significant pullbacks, the demand for convertible bonds may still exist [3] - The report suggests a non-typical barbell strategy focusing on sectors such as military industry, AI computing, and low-altitude economy, complemented by low-volatility dividends and high-cost performance varieties to navigate potential market fluctuations [3] Group 3: Home Appliance Industry - The company has developed a robust global manufacturing and sales system for air conditioning over more than 30 years, characterized by a stable shareholding structure and an experienced management team. Its growth model combines high cost-performance, channel flattening, and overseas localization [5] - The company has established a competitive advantage through product innovation, channel transformation, and supply chain optimization, with a business structure that supports both household and central air conditioning [5] Group 4: Food and Beverage Sector - The company reported a revenue of 17.087 billion yuan in the first half of 2025, a year-on-year increase of 10.6%, and a net profit of 1.287 billion yuan, up 33.2% year-on-year [7] - The food segment achieved a revenue of 5.382 billion yuan, growing 8.8% year-on-year, while the beverage segment generated 10.788 billion yuan, a 7.6% increase year-on-year, with tea beverages showing particularly strong performance [8] - The company is expected to maintain steady growth, with projected net profits of 2.3 billion yuan, 2.61 billion yuan, and 2.91 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 24.3%, 13.4%, and 11.7% [8]

Core Viewpoint - The launch of China's first pharmaceutical ETF fund aims to provide investors with exposure to leading companies in the chemical, biological, and traditional Chinese medicine sectors, capitalizing on the growth potential driven by innovation and demographic trends [1][5]. Industry Overview - The pharmaceutical industry is characterized by its essential nature, driven by a large population, aging demographics, and increasing GDP per capita, which supports long-term growth [5]. - By 2024, the proportion of the population aged 65 and above in China is expected to reach 15.6%, indicating a shift into a moderately aging society, which will further expand the pharmaceutical market [5]. Innovation and Growth - Innovative drugs are seen as a key driver for the pharmaceutical industry's growth, with the potential to unlock new value and re-evaluate medical asset worth [5]. - Domestic innovative drugs are anticipated to experience significant growth in 2024, supported by various internal and external factors, potentially leading to a "Davis Double Play" scenario [5]. - The integration of AI in drug development is expected to accelerate the research and development of new medications [5]. ETF Fund Details - The newly launched ETF fund (A class: 024985 / C class: 024986) will exclusively track the CSI Pharmaceutical Index, which includes leading companies in the chemical, biological, and traditional Chinese medicine sectors [1][19]. - The fund aims to provide a balanced investment approach, combining high-growth innovative drugs with more stable traditional Chinese medicine to mitigate volatility [1][19]. Performance Metrics - The pharmaceutical index has shown a significantly smaller decline compared to similar indices over the past five years, with positive returns over the last three years [14]. - The index's long-term annualized volatility and maximum drawdown are notably lower than those of comparable indices, indicating a more stable investment profile [14]. Key Constituents - The top ten constituents of the pharmaceutical index include major companies such as Heng Rui Medicine (14.91% weight), Pian Zai Ye (5.83%), and Yunnan Baiyao (4.81%), reflecting a diverse representation across the pharmaceutical sectors [13].

Group 1 - The A-share market in July showed steady progress, attracting investor attention towards public fund products, with many fund companies actively launching new products focused on China's sci-tech innovation sector [1][5] - Morgan Asset Management's new product launched in July became one of the largest actively managed quantitative funds in the market since 2024, targeting industries with growth potential such as green transformation and intelligent upgrades [3] - In July, a total of 20 new public fund products were introduced, with 10 of them specifically supporting the sci-tech sector, highlighting themes like robotics, innovative pharmaceuticals, and aerospace as popular topics [5]

Core Insights - The average return of actively managed equity funds has significantly improved, reaching 15.1% year-to-date as of August 6, with over 500 funds hitting historical net asset value highs [1][2] - There is a stark performance disparity among funds, with top performers achieving returns close to 130% while laggards have seen declines exceeding 18% [1][3] - The strong performance of leading funds is attributed to successful investments in sectors such as innovative pharmaceuticals, technology, and new consumer trends [2][3] Performance Summary - As of August 6, 127 actively managed equity funds have returns exceeding 50%, with 23 funds surpassing 80%, and 6 funds doubling their net asset value this year [2] - Specific funds like Changcheng Pharmaceutical Industry Select Mixed Fund and Bank of China Hong Kong Stock Connect Pharmaceutical Mixed Fund have returns of 129.97% and 117.54% respectively [2] - Funds focusing on innovative pharmaceuticals have been particularly successful, with several funds achieving returns over 90% in related sectors [2] Fund Management Trends - A significant number of high-performing funds are now implementing purchase limits due to increased investor interest and inflows, with nearly 30 funds announcing restrictions on large subscriptions [4] - Recent fund issuance has also seen a resurgence, with several funds raising over 1 billion yuan, indicating a growing market interest [4] - The trend of increasing fund management activity suggests that equity funds are becoming a key avenue for reallocating household savings [4] Market Outlook - The ongoing supportive policies for the capital market are expected to enhance investor risk appetite, with potential catalysts in technology, high-end manufacturing, and consumer sectors [5] - The release of semi-annual earnings from listed companies is anticipated to improve the effectiveness of investment strategies, particularly in sectors with concentrated catalysts [5]

Core Viewpoint - The performance of actively managed equity funds in the A-share market has rebounded significantly, with over 90% of products achieving net value growth this year, indicating a strong wealth effect and potential for a virtuous cycle in the market [1][4]. Group 1: Fund Performance - As of August 7, 2023, 4,598 actively managed equity funds were tracked, with 4,347 (94.54%) achieving net value growth this year [2]. - Notably, 127 funds recorded a net value growth rate exceeding 50%, and 6 funds surpassed 100% [2]. - A total of 1,126 funds reached new net value highs since their inception this year [2]. Group 2: Key Investment Themes - Innovation in pharmaceuticals and technology are identified as the two main drivers of net value growth for actively managed equity funds [2]. - The Changcheng Medical Industry Selected Mixed Fund led with a 129.97% net value growth rate, focusing heavily on innovative pharmaceuticals [2][3]. - The Yongying Technology Smart Selection Mixed Fund achieved a 91.23% net value growth rate, concentrating on the global cloud computing industry [3]. Group 3: Market Sentiment and Fund Flows - The recovery in actively managed equity fund performance is expected to enhance investor confidence, leading to increased fund subscriptions and market stability [4][5]. - The Yongying Advanced Manufacturing Smart Selection Mixed Fund's size grew from 1.762 billion to 13.845 billion yuan, while the Penghua Carbon Neutrality Theme Mixed Fund expanded from 1.035 billion to 10.863 billion yuan this year [4]. - Fund sales personnel reported a noticeable increase in investor interest and purchase intentions, with many public institutions accelerating the issuance of new funds, particularly in equity [5].

Group 1 - The article highlights the importance of weekly announcements from Sunday to Thursday, which include significant stock market updates such as suspensions, increases or decreases in holdings, investment wins, acquisitions, performance reports, unlocks, and high transfers [1] - Key announcements are marked in red to assist investors in identifying investment hotspots and preventing potential black swan events, providing ample time for analysis and selection of suitable listed companies [1] Group 2 - A company in the semiconductor sector has completed verification of some new products and received trial orders, focusing on storage chips, third-generation semiconductors, photovoltaics, and superconductors [1] - Another company is collaborating with humanoid robot enterprises to conduct material verification, with a focus on rare earth permanent magnets, humanoid robots, military industry, drones, and chips [1] - A company is advancing over ten innovative drug and medical device projects in the fields of innovative drugs, traditional Chinese medicine, medical devices, and ophthalmic medical care [1]

Group 1: Overview of Major Assets - In July, the A-share market approached 3600 points, with the 10-year government bond yield rising and commodities experiencing fluctuations [1][8] - The A-share market saw a strong performance, with the Shanghai Composite Index reaching a high of 3616 points on July 30, and closing at 3573 points on July 31, marking a 3.7% increase for the month [1][8] - The global stock indices generally rose, with the UK FT100 and Nasdaq leading the gains [1][8] Group 2: A-share Market Performance - Major broad-based indices in the A-share market rose, with the Shanghai Composite Index, CSI 300, ChiNext Index, and STAR Market Index increasing by 3.74%, 3.54%, 8.14%, and 4.43% respectively in July [13] - Growth and consumption styles led the market, with the growth and consumption indices rising by 6.19% and 5.35% respectively [13] - The steel and pharmaceutical sectors were among the top performers, with increases of 16.76% and 13.93% respectively [13] Group 3: Economic and Liquidity Conditions - Economic data in June showed divergence, with manufacturing PMI remaining in contraction territory, while industrial value-added growth exceeded expectations [3] - Social financing began to recover, indicating a marginal easing of monetary conditions [3] - Northbound capital saw a rebound in July, with margin trading balances rising above 190 billion yuan, and ETF trading volumes reaching new highs since April [3][8]